Q3 2017 EPS Estimates for KALA PHARMCTLS Raised by Wedbush (KALA)
KALA PHARMCTLS (NASDAQ:KALA) – Stock analysts at Wedbush boosted their Q3 2017 earnings per share estimates for shares of KALA PHARMCTLS in a research note issued to investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the company will post earnings per share of ($0.36) for the quarter, up from their prior forecast of ($0.38). Wedbush has a “Outperform” rating and a $46.00 price objective on the stock. Wedbush also issued estimates for KALA PHARMCTLS’s Q4 2017 earnings at ($0.35) EPS, FY2017 earnings at ($2.28) EPS and FY2019 earnings at ($1.13) EPS.
TRADEMARK VIOLATION WARNING: “Q3 2017 EPS Estimates for KALA PHARMCTLS Raised by Wedbush (KALA)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/09/15/q3-2017-eps-estimates-for-kala-pharmctls-raised-by-wedbush-kala.html.
Other equities analysts have also recently issued research reports about the company. Bank of America Corporation started coverage on KALA PHARMCTLS in a research note on Monday, August 14th. They set a “buy” rating and a $33.00 target price on the stock. Oppenheimer Holdings, Inc. started coverage on KALA PHARMCTLS in a research note on Tuesday, August 15th. They set an “outperform” rating and a $46.00 target price on the stock. Wells Fargo & Company started coverage on KALA PHARMCTLS in a research note on Monday, August 14th. They set an “outperform” rating and a $24.00 target price on the stock. Finally, J P Morgan Chase & Co started coverage on KALA PHARMCTLS in a research note on Monday, August 14th. They set an “overweight” rating and a $35.00 target price on the stock. Five research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $36.80.
KALA PHARMCTLS (NASDAQ KALA) opened at 26.58 on Friday. The stock’s 50 day moving average is $22.34 and its 200 day moving average is $20.70. KALA PHARMCTLS has a one year low of $16.38 and a one year high of $26.75. The stock’s market capitalization is $643.95 million.
In other news, major shareholder Associates L.L.C. Cdk purchased 215,000 shares of KALA PHARMCTLS stock in a transaction dated Thursday, July 20th. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $3,225,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Orbimed Advisors Llc purchased 319,333 shares of KALA PHARMCTLS stock in a transaction dated Tuesday, July 25th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,789,995.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 1,282,666 shares of company stock valued at $19,239,990.
About KALA PHARMCTLS
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for KALA PHARMCTLS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA PHARMCTLS and related companies with MarketBeat.com's FREE daily email newsletter.